Jointown Pharmaceutical

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Haier Biomedical 'Smart Blood City Network' Lands in Brazil

Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.

D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline

EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.

Insilico Medicine submitted a listing application to the Hong Kong Stock Exchange

On March 27, Insilico Medicine, an AI drug research and development company, once again submitted its listing application to the Hong Kong Stock Exchange.

Yanyin Technology raised tens of millions of yuan in angel round financing

Recently, Yanyin Technology announced that it has completed tens of millions of yuan in angel round financing, and the investor is Qiming Venture Partners.

China-Indonesia Joint Venture Surgical String Plant in Indonesia

Hengrui's MSCI ESG Rating Upgraded to A

Hengrui, as one of the leading pharmaceutical companies in innovation, has achieved continuous improvement in its MSCI ESG rating to "A" level, placing it at the forefront of the pharmaceutical industry in China.

EqualOcean | Southern Weekly 2022 'China Greenwashing List'

Nine companies have been listed on China's Greenwashing List, drawing wider attention to the issue of greenwashing.

EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part III）

Private enterprises are actively embracing the transformative era

Pure Global: The International Engine of Medical Technology Globalization

As a pioneer in international regulatory management and clinical solutions, Pure Global has evolved into an indispensable partner for medical technology companies. Through its outstanding data technology, seasoned industry expert team, and transnational capabilities, Pure Global empowers its partners to achieve global growth. Presently, Pure Global's services span more than 25 countries and regions, offering tailored solutions for the entire lifecycle of medical devices.

Ligatech Completes D Round of Financing of hundreds of Millions

Recently, Shanghai Ligatech Bioscience Co., Ltd(利格泰), located in Qingpu District, Shanghai, announced the completion of a D round of financing of hundreds of Millions.

Pharmaceutical Machine Vision Company aocheng Nets Tens of Millions in Round A

EqualOcean has learned that aocheng (Chinese: 奥乘智能), a machine vision inspection company in the pharmaceutical field, has recently closed tens of millions of CNY in round A financing.

Lanja has completed the Series A funding of hundred millions CNY

Shanghai Lanja Medical Technology Co., Ltd (“Lanja”) recently has announced the completion of the Series A funding of hundred millions CNY.

MGI Tech: Lead Life Science Through Intelligent Innovation

In the dynamic realm of bioscience, MGI Tech Co., Ltd. (MGI) has emerged as a torchbearer, captivating attention with its trailblazing achievements and relentless dedication to innovation.

Cataya Completes B Round of Financing of 250 Million

The synthetic biology company Shanghai Cataya Biotech Inc. (柯泰亚生物) has recently announced the completion of a RMB 250 million B round of financing.

RabPharma has completed the Series A+ funding of hundred millions CNY

Zhongshan RabPharma Biopharmaceutical Co., Ltd. (“RabPharma”) recently has announced the completion of the Series A+ funding of hundred millions CNY.

Powertight has completed a pre-Series A funding of hundred millions CNY

Powertight Biotechnology (Hangzhou) Co., Ltd. (“Powertight”) recently has announced the completion of a pre-Series A funding of hundred millions CNY.

Foremed Legend has completed the pre-Series A+ funding

Suzhou Foremed Legend Medical Technology Company, Ltd. (“Foremed Legend”) recently has announced the completion of pre-Series A+ funding.

Surgical Robotics Company Rovono Surgical Nets Nearly 200 Mn in Pre-B+ Round

EqualOcean has learned that Rovono Surgical(Chinese: 瑞龙诺赋), a laparoscopic surgical robot developer, has completed a pre-B+ round of financing of nearly CNY 200 million.

Bioprofile completed a Series A funding of hundred millions CNY

Shanghai Bioprofile Technology Company, Ltd. (“Bioprofile”) recently has announced the completion of hundred millions of CNY in Series A funding.